A61K 31/5365
Ortho- or peri-condensed with heterocyclic ring systems
Official title: ortho- or peri-condensed with heterocyclic ring systems
A61K31/5365 (Ortho- or peri-condensed with heterocyclic ring systems) appears on 323 US grants and 667 published applications in this corpus.
Search patents in A61K- Granted patents
- 323
- Published applications
- 667
- Assignees
- 290
- Inventors
- 1,597
- Latest grant
- 25 Aug 2026
Filings by year
| Year | Granted patents | Published applications |
|---|---|---|
| 1997 | 1 | 0 |
| 1998 | 0 | 0 |
| 1999 | 1 | 0 |
| 2000 | 2 | 0 |
| 2001 | 4 | 1 |
| 2002 | 2 | 3 |
| 2003 | 5 | 7 |
| 2004 | 0 | 7 |
| 2005 | 3 | 5 |
| 2006 | 3 | 8 |
| 2007 | 3 | 9 |
| 2008 | 0 | 11 |
| 2009 | 4 | 7 |
| 2010 | 3 | 3 |
| 2011 | 5 | 10 |
| 2012 | 4 | 11 |
| 2013 | 8 | 14 |
| 2014 | 12 | 25 |
| 2015 | 16 | 47 |
| 2016 | 19 | 53 |
| 2017 | 30 | 52 |
| 2018 | 29 | 56 |
| 2019 | 42 | 54 |
| 2020 | 28 | 40 |
| 2021 | 23 | 37 |
| 2022 | 17 | 39 |
| 2023 | 16 | 42 |
| 2024 | 14 | 39 |
| 2025 | 12 | 48 |
| 2026 | 17 | 39 |
By publication year. Applications have been published since 2001. 2026 runs to 8 Oct.
Recent patents
- Methods of treating RBP4 related diseases with triazolopyridines25 Aug 2026US 12,714,700 B2Belite Bio, Inc
- Combination therapy with a mutant IDH inhibitor and a Bcl-2 inhibitor25 Aug 2026US 12,714,712 B2Board of Regents, The University of Texas System
- Anticancer combination therapy with N-(1-acryloyl-azetidin-3-yl)-2-((1H-indazol-3-yl)amino)methyl)-1H-imidazole-5-carboxamide inhibitor of KRAS-G12C11 Aug 2026US 12,702,658 B2Astex Therapeutics Limited
- Unit dosage composition of AKT inhibitor7 Jul 2026US 12,673,061 B2Nanjing Chia Tai Tianqing Pharmaceutical Co., Ltd.
- Method of treating microbial infections2 Jun 2026US 12,642,804 B2The Regents of the University of California
- Raf-mek protein complex modulators and methods of use thereof1 Oct 2026US 2026/0297105 A1Gandeeva Therapeutics, Inc.
- Heterocyclic compounds useful as kcnt1 inhibitors24 Sep 2026US 2026/0285838 A1Actio Biosciences, Inc.
- Inhibitors of parg24 Sep 2026US 2026/0285875 A1858 Therapeutics, Inc.
- Sik2 modulators and uses thereof17 Sep 2026US 2026/0274820 A1Nimbus Salacia, Inc.
- Capsid inhibitors for the treatment of hiv10 Sep 2026US 2026/0263436 A1Gilead Sciences, Inc.
Most cited
By later US patents
- Cytotoxic agents comprising new maytansinoids227US 7,276,497 B2ImmunoGen, Inc. · 2007
- Organic compounds95US 8,664,207 B2Intra-Cellular Therapies, Inc. · 2014
- Nitrogen containing heterocyclic compounds and medicines containing the same81US 7,265,108 B2Eisai Co., Ltd. · 2007
- Nitrogen containing heterocyclic compounds and medicines containing the same54US 6,995,144 B2Eisai Co., Ltd. · 2006
- Folate receptor 1 antibodies and immunoconjugates and uses thereof49US 8,557,966 B2ImmunoGen, Inc. · 2013